These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 12751039

  • 1. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir.
    Razonable RR, van Cruijsen H, Brown RA, Wilson JA, Harmsen WS, Wiesner RH, Smith TF, Paya CV.
    J Infect Dis; 2003 Jun 01; 187(11):1801-8. PubMed ID: 12751039
    [Abstract] [Full Text] [Related]

  • 2. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
    Torre-Cisneros J, Caston-Osorio JJ, Martín C, Rivero A, Doblas A, Rojas R, Gómez P, Martínez F, Torres A.
    Enferm Infecc Microbiol Clin; 2010 Jan 01; 28(1):6-12. PubMed ID: 19409666
    [Abstract] [Full Text] [Related]

  • 3. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.
    Paya CV, Wilson JA, Espy MJ, Sia IG, DeBernardi MJ, Smith TF, Patel R, Jenkins G, Harmsen WS, Vanness DJ, Wiesner RH.
    J Infect Dis; 2002 Apr 01; 185(7):854-60. PubMed ID: 11920308
    [Abstract] [Full Text] [Related]

  • 4. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.
    Strippoli GF, Hodson EM, Jones C, Craig JC.
    Transplantation; 2006 Jan 27; 81(2):139-45. PubMed ID: 16436954
    [Abstract] [Full Text] [Related]

  • 5. Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients.
    Monforte V, Román A, Gavaldà J, Bravo C, Gispert P, Pahissa A, Morell F.
    Transplant Proc; 2005 Nov 27; 37(9):4039-42. PubMed ID: 16386621
    [Abstract] [Full Text] [Related]

  • 6. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ, Busuttil RW.
    Transplantation; 2003 Jan 27; 75(2):229-33. PubMed ID: 12548129
    [Abstract] [Full Text] [Related]

  • 7. Response of asymptomatic cytomegalovirus viraemia to oral ganciclovir 3 g/day or 6 g/day in HIV-infected patients.
    Grzywacz M, Deayton JR, Bowen EF, Wilson P, Emery VC, Johnson MA, Griffiths PD.
    J Med Virol; 1999 Nov 27; 59(3):323-8. PubMed ID: 10502264
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.
    Palmer SM, Grinnan DC, Diane Reams B, Steele MP, Messier RH, Duane Davis R.
    Clin Transplant; 2004 Apr 27; 18(2):179-85. PubMed ID: 15016133
    [Abstract] [Full Text] [Related]

  • 10. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease.
    Humar A, Kumar D, Boivin G, Caliendo AM.
    J Infect Dis; 2002 Sep 15; 186(6):829-33. PubMed ID: 12198618
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
    Reischig T, Jindra P, Hes O, Bouda M, Kormunda S, Treska V.
    Transplantation; 2009 Feb 15; 87(3):436-44. PubMed ID: 19202451
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors.
    Winston DJ, Busuttil RW.
    Transplantation; 2004 Jan 27; 77(2):305-8. PubMed ID: 14742998
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.